IndietroDisorders of Pulmonary Circulation: Pulmonary Hypertension
Guida di studio - Note intelligenti
Appunti personalizzati basati sui tuoi materiali, ampliati con definizioni chiave, esempi e contesto.
Disorders of Pulmonary Circulation
Introduction
Disorders of pulmonary circulation primarily affect the blood flow through the lungs, with Pulmonary Hypertension (PH) being a major pathological condition. PH is characterized by elevated pressure in the pulmonary arteries, leading to significant cardiovascular and respiratory complications. Understanding the pathophysiology, classification, clinical presentation, diagnosis, and treatment of PH is essential for students of anatomy and physiology.
Pulmonary Hypertension
Definition and Etiology
Pulmonary Hypertension (PH) is defined as elevated blood pressure in the pulmonary arterial system.
Key pathological features include vasoconstriction, smooth muscle cell (SMC) proliferation, inflammation, and thrombosis.
PH has multiple etiologies, including idiopathic, heritable, drug-induced, and disease-induced causes.
Classification of Pulmonary Hypertension
Groups and Common Etiologies
Pulmonary Hypertension is classified into five groups based on underlying causes:
Group | Name | Common Etiologies |
|---|---|---|
I | Pulmonary Arterial Hypertension (PAH) | Idiopathic, Heritable, Drug Induced, Disease Induced (HIV, portal HTN, connective tissue disorders) |
II | Pulmonary HTN due to left heart disease | Left diastolic/systolic failure, Left valvular disorders |
III | Pulmonary HTN due to lung disease/hypoxia | COPD, interstitial lung disease, Obstructive sleep apnea |
IV | Chronic Thromboembolic Pulmonary HTN (CTEPH) | Chronic thrombotic/embolic disorders, Arteritis |
V | Pulmonary HTN due to miscellaneous disorders | Sarcoidosis, Chronic kidney failure, Chronic hemolytic anemia |
Group I PAH
Etiologies
Idiopathic: No identifiable cause.
Heritable: 70% of genetic cases are due to mutations in the bone morphogenetic protein receptor type II gene (BMPR2), which codes for TGF-β receptors that inhibit arterial SMC and endothelial cell proliferation.
Drug Induced: Fenfluramine, dexfenfluramine (off market), amphetamines, cocaine, some chemotherapy agents.
Disease Induced: HIV, portal hypertension, connective tissue disorders.
Group II PAH
Pathophysiology
Secondary to left heart failure and mitral valve disorders (stenosis).
Increased left atrial pressure leads to increased pulmonary venous and arterial pressure.
Results in hypertrophy and thickening of pulmonary artery vessels, causing sustained pulmonary hypertension.
Group III PAH
Pathophysiology
Pulmonary circulation vasoconstricts in response to hypoxemia.
Increased pulmonary artery pressure and resistance (afterload).
Leads to right ventricular hypertrophy (early) and dilation (late), progressing to right ventricular failure.
Group IV PAH
Pathophysiology
Secondary to chronic thrombus/emboli.
Impaired pulmonary circulation and hypoxemia.
Pathophysiology of Pulmonary Hypertension
Cellular and Molecular Mechanisms
Endothelial dysfunction leads to impaired regulation of vascular tone and cell proliferation.
SMC dysfunction results in excessive proliferation and inflammation.
Matrix changes, platelet activation, and inflammatory cell infiltration contribute to vasoconstriction and thrombosis.
Common features include increased pulmonary arteriole contractility, endothelial dysfunction, proliferation of endothelial and SMCs, microthrombi, and inflammatory mediator infiltration.
End result: Vascular lumen narrows, increasing resistance.
Normal Regulation Pathways
Mechanisms of Pulmonary Endothelial Regulation
Nitric Oxide (NO) Pathway: NO vasodilates, inhibits SMC proliferation, and platelet aggregation.
Prostacyclin (PGI2)/Thromboxane (TBXA2) Pathway: PGI2 vasodilates, inhibits SMC proliferation, and platelet aggregation; TBXA2 vasoconstricts, stimulates SMC proliferation, and platelet aggregation.
Endothelin-1 (ET) Pathway: ETA receptor (SMC): vasoconstriction, SMC proliferation/hypertrophy, fibrosis; ETB receptor (SMC): vasoconstriction; ETB (endothelial cell): NO and PGI2 production.
Pathophysiology of PAH: Key Pathways
Nitric Oxide Pathway
Decreased eNOS expression/activity leads to reduced NO production.
Results in vasoconstriction, SMC proliferation, inflammation, platelet aggregation, and thrombosis.
Equation:
Prostacyclin Pathway
Shift toward increased Thromboxane A2 and decreased prostacyclin (PGI2).
Results in vasoconstriction, SMC proliferation, inflammation, platelet aggregation, and thrombosis.
Endothelin-1 Pathway
Increased ET-1 production.
ETA and ETB expression on SMCs leads to vasoconstriction, hypertrophy, proliferation, and fibrosis.
ETB expression on endothelial cells increases NO and PGI2 production.
Clinical Presentation
Signs and Symptoms
Signs of PAH: Elevated pulmonary artery mean pressure (>25 mmHg), pulmonary capillary wedge pressure (<15 mmHg), right ventricular hypertrophy, right atrial enlargement.
Right Heart Failure: Lower extremity edema, abdominal edema, jugular venous distension (JVD), dyspnea, exertional chest pain.
Progression to Left Sided Heart Failure: Decreased cardiac output, fatigue, weakness, pulmonary edema, orthopnea.
Diagnosis
Diagnostic Criteria
Clinical presentation plus right heart catheterization.
Elevated pulmonary artery mean pressure (>25 mmHg).
Pulmonary capillary wedge pressure (<15 mmHg).
Equation:
Treatment of PAH
Pharmacological Approaches
Prostacyclin Analogs: Mimic PGI2 to promote vasodilation and inhibit SMC proliferation.
Guanylate Cyclase Stimulators: Enhance NO signaling for vasodilation.
Phosphodiesterase-5 Inhibitors: Prevent breakdown of cGMP, promoting vasodilation.
Endothelin-1 Receptor Antagonists: Block ETA/ETB receptors to reduce vasoconstriction and SMC proliferation.
Example: Drugs such as sildenafil (PDE-5 inhibitor), bosentan (endothelin receptor antagonist), and epoprostenol (prostacyclin analog) are used in PAH management.
Summary Table: Key Pathways and Effects
Pathway | Normal Effect | PAH Effect |
|---|---|---|
Nitric Oxide | Vasodilation, inhibits SMC proliferation, platelet aggregation | Decreased NO: vasoconstriction, SMC proliferation, thrombosis |
Prostacyclin (PGI2) | Vasodilation, inhibits SMC proliferation, platelet aggregation | Decreased PGI2: vasoconstriction, SMC proliferation, thrombosis |
Thromboxane (TBXA2) | Vasoconstriction, stimulates SMC proliferation, platelet aggregation | Increased TBXA2: enhanced vasoconstriction, SMC proliferation |
Endothelin-1 | Regulates vasoconstriction and vasodilation via ETA/ETB receptors | Increased ET-1: vasoconstriction, SMC proliferation, fibrosis |
Additional info:
PAH is a progressive disease that can lead to right and left heart failure if untreated.
Early diagnosis and targeted therapy are crucial for improving patient outcomes.